REPLICOR

Replicor is a clinical-stage biopharmaceutical company developing NUCLEIC ACID POLYMERS (NAPs). These compounds are oligonucleotides whose antiviral activity is strictly dependent on the sequence-independent activity of phosphorothioate oligonucleotides as biocompatible polymers that interact with exposed hydrophobic surfaces in proteins. This exposed hydrophobic feature is rare in mammals but is common in the life cycles of many different infectious agents. The high affinity "annealing" of NAPs along these hydrophobic surfaces is not sensitive to the development of drug resistance (like small molecules and siRNA) and efficiently blocks structural reorganizations essential for viral replication... As REP 2139 targets both hepatitis B (HBV) and hepatitis delta (HDV), Replicor has focused its efforts on developing a cure for HBV and HDV with REP 2139-based combination therapies. Pre-clinical and clinical studies (including four proof of concept phase II clinical trials) have..

Primary location: Montreal Canada